Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 10/20 | 0.35 |
| ▸ | CA2 | P00918 | 10/20 | 0.35 |
| ▸ | CA9 | Q16790 | 9/20 | 0.35 |
| ▸ | CA12 | O43570 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.34 |
| ▸ | CA7 | P43166 | 3/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.34 |
| ▸ | CA3 | P07451 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.34 |
| ▸ | CA6 | P23280 | 2/20 | 0.34 |
| ▸ | CA5A | P35218 | 2/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16465846 | 0.98 | CES1 (0.39) | CES1CA1CA2CA9CA12 | |
| SCHEMBL29219352 | 0.95 | CES1 (0.42) | CES1CA1CA2CA9CA12 | |
| SCHEMBL28142304 | 0.95 | CES1 (0.42) | CES1CA1CA2CA9CA12 | |
| SCHEMBL2535307 | 0.93 | CES1 (0.37) | CES1CA1CA2CA9CA12 | |
| Boric Acid SCHEMBL461466 | 0.91 | CES1 (0.36) | CES1CA1CA2CA9CA12 | |
| SCHEMBL27916215 | 0.91 | TSHR (0.37) | CES1CA1CA2 | |
| SCHEMBL28993175 | 0.90 | CES1 (0.39) | CES1CA1CA2CA9CA12 | |
| Boric Acid SCHEMBL28543765 | 0.90 | CES1 (0.39) | CES1CA1CA2CA9CA12 | |
| Boric Acid SCHEMBL29150377 | 0.90 | CES1 (0.39) | CES1CA1CA2CA9CA12 | |
| SCHEMBL28993164 | 0.90 | CES1 (0.39) | CES1CA1CA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024141443-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS SIK MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-07-04 | — | — | WO | disclosed |
| WO-2023139084-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139085-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| CN-115322199-A | Compounds and their use in the treatment of schistosomiasis | 默克专利股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-110461848-B | Compounds and their use in the treatment of schistosomiasis | 默克专利股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20210230169-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF FASCIOLIASIS | MERCK PATENT GMBH (DE) | 2021-07-29 | — | — | US | disclosed |
| US-11046700-B2 | Substituted imidazo[1,2-a]pyrazines, pyrazolo[1,5-c]pyrimidines, pyrazolo[1,5-a]pyridines, and purines for the treatment of schistosomiasis | MERCK PATENT GMBH (DE) | 2021-06-29 | — | — | US | disclosed |
| EP-3823728-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF FASCIOLIASIS | Merck Patent GmbH (DE) | 2021-05-26 | — | — | EP | disclosed |
| CN-112512636-A | Compounds for the treatment of fascioliasis | 默克专利股份有限公司 | 2021-03-16 | — | — | CN | disclosed |
| US-20200123158-A1 | NOVEL COMPOUNDS AND THEIR USE IN THE TREATMENT OF SCHISTOSOMIASIS | SALVENSIS (GB) | 2020-04-23 | — | — | US | disclosed |
| EP-3181133-B1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018130853-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF SCHISTOSOMIASIS | SALVENSIS (GB) | 2018-07-19 | — | — | WO | disclosed |
| EP-3181133-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | Pfizer Inc (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2654750-B1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2017-03-08 | — | — | EP | disclosed |
| CN-103260622-B | Novel fused pyridine compounds as casein kinase inhibitors | PFIZER | 2015-05-13 | — | — | CN | disclosed |
| EP-2654750-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | Pfizer Inc (US) | 2013-10-30 | — | — | EP | disclosed |
| US-8536164-B2 | Fused pyridine compounds as casein kinase inhibitors | PFIZER INC. (US) | 2013-09-17 | — | — | US | disclosed |
| CN-103260622-A | Novel fused pyridine compounds as casein kinase inhibitors | PFIZER | 2013-08-21 | — | — | CN | disclosed |
| WO-2012085721-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157440-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER INC | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230169-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF FASCIOLIASIS | SLC10A1, SLC10A2, MGST3 | CES1 638/4885CA1 2210/4885CA2 472/4885 |
| US-11046700-B2 | Substituted imidazo[1,2-a]pyrazines, pyrazolo[1,5-c]pyrimidines, pyrazolo[1,5-a]pyridines, and purines for the treatment of schistosomiasis | P2RY1, P2RX5, TPMT | CES1 1417/4885CA1 2417/4885CA2 532/4885 |
| US-20200123158-A1 | NOVEL COMPOUNDS AND THEIR USE IN THE TREATMENT OF SCHISTOSOMIASIS | SI, SLC10A2, ALPI | CES1 1128/4885CA1 1468/4885CA2 220/4885 |
| US-20120157440-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | CSNK1A1, CSNK1A1L, CSNK1E | CES1 919/4885CA1 1839/4885CA2 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.